U.S. health authorities have approved a groundbreaking gene therapy designed to treat a rare inherited form of hearing loss, marking a major step forward in the fight against genetic hearing impairment.
The therapy, known as Otarmeni and developed by Regeneron Pharmaceuticals, targets mutations in the OTOF gene—a critical component responsible for transmitting sound signals from the inner ear to the brain. The condition affects an estimated 50 newborns annually in the United States.
Hearing impairment occurs in about two to three out of every 1,000 children born in the U.S., with more than half of early-onset cases linked to genetic causes.
Approved under an accelerated pathway by the U.S. Food and Drug Administration, the treatment is administered as a one-time injection directly into the ear by a surgeon. It is intended for both children and adults with severe-to-profound hearing loss caused by specific
genetic mutations.Despite the typically high cost of gene therapies—often running into millions of dollars per patient—Regeneron announced that eligible patients in the U.S. will receive the treatment free of charge.
Clinical trials involving 20 pediatric patients aged between 10 months and 16 years showed promising results, with at least 80 percent experiencing significant hearing improvement within months.
Medical experts have described the development as transformative. According to Eliot Shearer, who participated in the trial, the approval signals a new era where continuous, natural hearing may be restored for patients with genetic hearing loss.
For families, the impact has been life-changing. Sierra Smith, whose infant son underwent the therapy, shared her emotional experience, noting that her child can now respond to sound, enjoy music, and recognize voices—milestones that once seemed out of reach.
The breakthrough is expected to pave the way for similar gene-based treatments targeting other forms of hereditary hearing loss.
